RxDoctor Payments Data

Helen Cohen

Women's Health · Scarborough, MENPI 1457018939

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,281 of the $3,019 with a category attached, or 75.6%. 11 manufacturers reported payments, led by Axonics, Inc. at 45.8% of the total. Reporting peaked in 2024 at $1,453 and has fallen 88.2% since, to $172 in 2025.

$3,019in general payments, 2019–2025

Across 96 payments — averaging $31.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Medtronic$538
  • Sumitomo Pharma America, Inc.$294
  • Astellas Pharma US Inc$266
  • Urovant Sciences Inc$205
  • Mission Pharmacal Company$137
  • plus $196 from 5 others

What the payments were for

  • Travel & lodging$73824%
  • Food & beverage$2,28176%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few women's health providers in Maineto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$55,417
Medicare patients
441
Services billed
1,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron229$193,611
GemtesaVibegron81$74,699
Estradiol240$20,681
PremarinEstrogens, Conjugated21$9,141
Trospium Chloride ErTrospium Chloride36$7,524
Methenamine Hippurate44$4,871
Solifenacin Succinate106$4,251
Trospium Chloride71$4,108
YuvafemEstradiol17$2,914
Oxybutynin Chloride ErOxybutynin Chloride67$2,520
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst92$1,035
Fesoterodine Fumarate ErFesoterodine Fumarate16$991
Cephalexin80$742
Hydroxyzine Hcl11$152
Baclofen15$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$266$193,611229 claims
Sumitomo Pharma America, Inc.Gemtesa$294$74,69981 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few women's health providers in Maineon file to place this against a meaningful peer group, so we don't.

Other women's health in Scarborough

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →